Dosing & Uses
Dosage Forms & Strengths
injection, freeze-dried suspension
- ≥2.5 IU/mL
Rabies Preexposure Immunization
Primary
- 1 mL IM (deltoid region) x3 doses
- Administer on days 0, 7, and 21 or 28
Booster
- 1 mL IM (deltoid region) to maintain a serum titer >1:5 serum dilution by RFFIT
Frequency for testing serum titers
-
Continuous risk
- Test serum for rabies antibodies q6month in persons working with live rabies virus in research laboratories and in vaccine production facilities (continuous risk category)
-
Frequent risk
- Other laboratory workers (eg, those performing rabies diagnostic testing), cavers, veterinarians and staff, animal-control and wildlife officers in areas where rabies is enzootic, and bat handlers regardless of location
- If titer inadequate, administer single booster dose of vaccine
-
Infrequent risk
- Veterinarians, veterinary students, and terrestrial animal-control and wildlife officers, working in areas of low rabies endemicity and certain at-risk international travelers who have completed a full preexposure vaccination series with licensed vaccines and according to schedule do not require routine booster serologic verification of detectable antibody titers or routine preexposure booster doses of vaccine
Rabies Postexposure Immunization
Unimmunized individuals
- 1 mL IM x5 doses
- Administer on days 0, 3, 7, 14, and 28 in conjunction with administration of human rabies immune globulin (HRIG) on day 0
- HRIG: 20 IU/kg; if anatomically feasible, the full dose should be infiltrated around and into the wound(s), and any remaining volume should be administered IM at an anatomical site distant from vaccine administration
Previously immunized individuals
- 1 mL IM x2 doses on days 0 and 3
Additional Information
Current vaccination schedules available at https://www.cdc.gov/vaccines/schedules/hcp/index.html
Dosage Forms & Strengths
injection, freeze-dried suspension
- ≥2.5 IU/mL
Rabies Preexposure Immunization
Vaccination is recommended for children living in or visiting countries where exposure to rabid animals is a constant threat; worldwide statistics indicate children are more at risk than adults
Primary
- 1 mL IM (deltoid region, in small children and infants anterolateral region of thigh) x3 doses
- Administer on days 0, 7, and 21 or 28
Booster
- 1 mL IM (deltoid region) to maintain a serum titer >1:5 serum dilution by RFFIT
Frequency for testing serum titers
-
Continuous risk
- Test serum for rabies antibodies q6month in persons working with live rabies virus in research laboratories and in vaccine production facilities (continuous risk category)
-
Frequent risk
- Other laboratory workers (eg, those performing rabies diagnostic testing), cavers, veterinarians and staff, animal-control and wildlife officers in areas where rabies is enzootic, and bat handlers regardless of location
- If titer inadequate, administer single booster dose of vaccine
-
Infrequent risk
- Veterinarians, veterinary students, and terrestrial animal-control and wildlife officers, working in areas of low rabies endemicity and certain at-risk international travelers who have completed a full preexposure vaccination series with licensed vaccines and according to schedule do not require routine booster serologic verification of detectable antibody titers or routine preexposure booster doses of vaccine
Rabies Postexposure Immunization
Unimmunized individuals
- 1 mL IM x5 doses
- Administer on days 0, 3, 7, 14, and 28 in conjunction with administration of human rabies immune globulin (HRIG) on day 0
- HRIG: 20 IU/kg; if anatomically feasible, the full dose should be infiltrated around and into the wound(s), and any remaining volume should be administered IM at an anatomical site distant from vaccine administration
Previously immunized individuals
- 1 mL IM x2 doses on days 0 and 3
Additional Information
Current vaccination schedules available at https://www.cdc.gov/vaccines/schedules/hcp/index.html
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (1)
- belimumab
belimumab decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.
Serious - Use Alternative (37)
- adalimumab
adalimumab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- alefacept
alefacept decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- anakinra
anakinra decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- antithymocyte globulin equine
antithymocyte globulin equine decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- antithymocyte globulin rabbit
antithymocyte globulin rabbit decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- azathioprine
azathioprine decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- basiliximab
basiliximab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- budesonide
budesonide decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.
- canakinumab
canakinumab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressant may interfere with development of active immunity.
- cortisone
cortisone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.
- deflazacort
deflazacort decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.
- dexamethasone
dexamethasone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.
- elivaldogene autotemcel
elivaldogene autotemcel, rabies vaccine. Either decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. .
- etanercept
etanercept decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- everolimus
everolimus decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- fludrocortisone
fludrocortisone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.
- glatiramer
glatiramer decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- golimumab
golimumab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- hydrocortisone
hydrocortisone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.
- hydroxychloroquine sulfate
hydroxychloroquine sulfate decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- infliximab
infliximab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- leflunomide
leflunomide decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- methylprednisolone
methylprednisolone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.
- muromonab CD3
muromonab CD3 decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- mycophenolate
mycophenolate decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- ocrelizumab
ocrelizumab decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live-attenuated or live vaccines is not recommended during ocrelizumab treatment and until B-cell repletion.
- ofatumumab SC
ofatumumab SC decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 2 weeks before initiating ofatumumab SC for inactivated vaccines, and whenever possible.
- prednisolone
prednisolone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.
- prednisone
prednisone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.
- rilonacept
rilonacept decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- secukinumab
secukinumab decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating secukinumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with secukinumab may not elicit an immune response sufficient to prevent disease.
- siponimod
siponimod decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Pause vaccinations beginning 1 week before initiating siponimod and for 4 weeks after stopping treatment. Coadministration with live attenuated vaccines may increase infection risk.
- sirolimus
sirolimus decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- tacrolimus
tacrolimus decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- temsirolimus
temsirolimus decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- tocilizumab
tocilizumab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
- triamcinolone acetonide injectable suspension
triamcinolone acetonide injectable suspension decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.
Monitor Closely (20)
- certolizumab pegol
certolizumab pegol decreases effects of rabies vaccine by pharmacodynamic antagonism. Use Caution/Monitor.
- cyclosporine
cyclosporine decreases effects of rabies vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). .
- ibrutinib
ibrutinib decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .
- ifosfamide
ifosfamide decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .
- lomustine
lomustine decreases effects of rabies vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .
- mechlorethamine
mechlorethamine decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .
- melphalan
melphalan decreases effects of rabies vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .
- mercaptopurine
mercaptopurine decreases effects of rabies vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressants may interfere with development of active immunity.
- methotrexate
methotrexate decreases effects of rabies vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Concomitant administration of methotrexate can decrease the immunological response of vaccines.
- onasemnogene abeparvovec
onasemnogene abeparvovec decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Adjust vaccinations to accommodate concomitant corticosteroid administration prior to and following onasemnogene abeparvovec infusion. When initiating systemic corticosteriod therapy, wait 2 weeks after an inactivated vaccine.
- oxaliplatin
oxaliplatin decreases effects of rabies vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .
- ponesimod
ponesimod decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. If possible, complete all age-appropriate vaccinations at least 4 weeks before initiating ponesimod.
- procarbazine
procarbazine decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .
- rabies immune globulin, human (RIG)
rabies immune globulin, human (RIG) decreases effects of rabies vaccine by Other (see comment). Use Caution/Monitor. Comment: RIG may be administered concurrently with and up to 8 days after rabies vaccine. High dose rabies immunoglobulin may impair response to active immunization. .
- rituximab
rituximab, rabies vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab.
- rituximab-hyaluronidase
rituximab-hyaluronidase, rabies vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab.
- satralizumab
satralizumab decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines. At least 2 weeks before initiating for non-live vaccines. .
- tralokinumab
tralokinumab will decrease the level or effect of rabies vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines.
- ustekinumab
ustekinumab decreases effects of rabies vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease.
- voclosporin
voclosporin decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.
Minor (2)
- chloroquine
chloroquine decreases effects of rabies vaccine by pharmacodynamic antagonism. Minor/Significance Unknown. Immunosuppressants may interfere with development of active immunity.
- ozanimod
ozanimod decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Minor/Significance Unknown. No clinical data are available on the efficacy and safety of vaccinations in patients taking ozanimod. Vaccinations may be less effective if coadministered with ozanimod.
Adverse Effects
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), submit an online report at https://vaers.hhs.gov/reportevent.html or call 1-800-822-7967
>10%
Injection site reactions (eg, pain, erythema, swelling or itching) (25%)
Headache (20%)
Nausea (20%)
Abdominal pain (20%)
Muscle aches (20%)
Dizziness (20%)
1-10%
Serum sickness (7%)
Postmarketing Reports
Blood and lymphatic system disorders: Lymphadenopathy
Immune system disorders: Anaphylactic reaction, serum sickness type reaction, dermatitis allergic, pruritus (itching), edema
Nervous system disorders: Paresthesia, neuropathy, convulsion, encephalitis, Guillain-Barré-like syndrome
Gastrointestinal disorders: Vomiting, diarrhea
Musculoskeletal and connective tissue disorders: Arthralgia
General disorders and administration site conditions: Asthenia, malaise, fever and chills (shivering), injection site hematoma
Respiratory, thoracic, and mediastinal disorders: Wheezing, dyspnea
Warnings
Contraindications
Preexposure prophylaxis
- Known life-threatening hypersensitivity to vaccine, neomycin, or any component of a vaccine
Postexposure prophylaxis
- None
Cautions
Do not inject vaccine into gluteal area as administration in this area may result in lower neutralizing antibody titers
The product is provided in a single dose vial; because the single dose vial contains no preservative, it is not to be used as a multidose vial for intradermal injection
In both pre-exposure and postexposure immunization, the full 1.0 mL dose should be given intramuscularly
When dose must be administered to person with history of hypersensitivity, antihistamines may be given; have epinephrine (1:1000) and other appropriate agents readily available to counteract anaphylactic reactions while carefully monitoring after immunization
Serum sickness type reactions reported in persons receiving booster doses for preexposure prophylaxis; characterized by onset ~2-21 days post-booster, presents with generalized urticaria, and may also include arthralgia, arthritis, angioedema, nausea, vomiting, fever, and malaise
Rare cases of neurologic illness resembling Guillain-Barré syndrome, a transient neuroparalytic illness, that resolved without sequelae in 12 weeks, and a focal subacute central nervous system disorder temporally associated with HDCV, reported
Product contains albumin, a derivative of human blood; based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD); there is theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote; no cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products
Vaccination may not protect 100% of vaccinated individuals
In adults and children, the vaccine should be injected into deltoid muscle; in infants and small children, the anterolateral aspect of the thigh is preferable
While concentration of antibiotics in each dose of vaccine is extremely small, persons with known hypersensitivity to any of these agents, or any other component of the vaccine, could manifest an allergic reaction; while the risk is small, it should be weighed in light of potential risk of contracting rabies
All serious systemic neuroparalytic or anaphylactic reactions to a rabies vaccine should be immediately reported to VAERS at 1-800-822-7967 (http://vaers.hhs.gov) or Sanofi Pasteur Inc., 1-800-VACCINE (1-800-822-2463)
Drug interaction overview
-
Immunosuppressive drugs
- Corticosteroids or other immunosuppressive can interfere with the development of active immunity and predispose the patient to developing rabies
- Do not administer immunosuppressive agents during postexposure therapy, unless essential for the treatment of other conditions
- When rabies postexposure prophylaxis is administered to persons receiving steroids or other immunosuppressive therapy, test for rabies antibody to ensure that an adequate response has developed
Pregnancy & Lactation
Pregnancy
Preexposure
- Animal reproduction studies have not been conducted
- It is also not known whether rabies vaccine can cause fetal harm when administered to pregnant women or can affect reproductive capacity
- Administer to pregnant women only if potential benefits outweigh potential risks
- If there is substantial risk of exposure to rabies, preexposure prophylaxis may also be indicated during pregnancy
Postexposure
- Because of the potential consequences of inadequately treated rabies exposure and limited data that indicate that fetal abnormalities have not been associated with rabies vaccination, pregnancy is not considered a contraindication to postexposure prophylaxis
Lactation
Unknown if excreted in human milk; exercise caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Inactivated virus vaccine provides immunity to rabies by eliciting an active immune response
Pharmacokinetics
Onset (antibodies): 7-10 days
Duration (antibodies): >1 year
Peak Plasma Time (antibodies): 30-60 days
Administration
IM Preparation
Using the longer of the 2 needles supplied, transfer the entire contents of provided diluent into vaccine vial to reconstitute the freeze-dried vaccine
Mix gently to avoid foaming
The creamy white to orange freeze-dried vaccine dissolves to a pink-to-red suspension
Withdraw total amount of dissolved vaccine into the syringe and replace long needle with smaller needle for IM injection
IM Administration
Adults and older children: Inject IM in deltoid muscle
Infants and small children: Inject IM in anterolateral aspect of the thigh
Do not inject in gluteal area; may result in lower neutralizing antibody titers
Storage
Refrigerate at 2-8ºC (35-46ºF)
Do not freeze
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Imovax Rabies Vaccine (PF) intramuscular - | 2.5 unit vial |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
rabies vaccine,human diploid (PF) intramuscular
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2022 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
